PharmaShots | Incisive News in 3 Shots

Subscribe Now

X-Linked Hypohidrotic Ectodermal Dysplasia

EspeRare's ER-004 Receives the US FDA's Breakthrough Therapy Designation for Prenatal Treatment of XLHED

EspeRare's ER-004 Receives the US FDA's Breakthrough Therapy Designation for Prenatal Treatment of XLHED

July 6, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us